Berenberg raises Redcare Pharmacy stock target to EUR 102.00
Published on 10/26/2026 at 10:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst targets and quarterly dates
- Redcare Pharmacy raised its 2026 total revenue growth guidance to 16 percent to 18 percent on September 28, 2026.
- Berenberg lifted its target from EUR 94.00 to EUR 102.00 on October 7, 2026.
- Redcare Pharmacy stock trades at EUR 78.23 at 10:53 a.m. CET at Lang & Schwarz on October 26, 2026, plus 0.42 percent versus the Xetra close of October 23, 2026.
Redcare Pharmacy (ISIN NL0012044747) was trading at EUR 78.23 at Lang & Schwarz on October 26, 2026 at 10:53 a.m. CET, up 0.42 percent versus the Xetra close of October 23, 2026 at EUR 77.90. MarketScreener reported on October 7, 2026 that Berenberg raised its price target from EUR 94.00 to EUR 102.00, while MPCM lifted its target from EUR 116.00 to EUR 120.00.
Guidance puts German Rx first
NewMediaWire carried Redcare Pharmacy's September 28, 2026 release, which raised full-year 2026 total revenue growth guidance to 16 percent to 18 percent from 15 percent to 17 percent. The change made prescription revenue in Germany the central operating measure.
The same release put full-year 2026 German Rx revenue at EUR 730 million to EUR 760 million, up from EUR 680 million to EUR 720 million previously. It also reported preliminary German Rx growth of 56 percent in the third quarter of 2026 and confirmed adjusted EBITDA margin guidance of 2.5 percent to 3.0 percent.
What will the October figures test?
The October 29, 2026 interim statement will show whether the preliminary third-quarter German Rx growth of 56 percent translated into the full reported period. The updated guidance also implies a sharper test for prescription demand than for non-Rx sales, whose 2026 growth guidance remained at 10 percent to 12 percent.
Analyst targets meet the next report
Berenberg's move to EUR 102.00 from EUR 94.00 and MPCM's move to EUR 120.00 from EUR 116.00 both followed the September guidance increase, according to MarketScreener on October 7, 2026. The next two dated company events are the Q3 2026 interim statement on October 29, 2026 and the 2026 annual report on March 4, 2027, both listed in the guidance release.
Stock remains below its yearly high
Redcare Pharmacy's 52-week range is EUR 30.20 to EUR 82.55, while its market capitalization is EUR 1.6 billion as of October 26, 2026. The stock therefore remains EUR 4.32 below the current 52-week high, keeping the upcoming report central to the valuation debate.
The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy stock facts
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC.DE
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 26, 2026, 10:53 a.m. CET): EUR 78.23
- Change versus Xetra close: plus 0.42 percent
- Xetra close (October 23, 2026): EUR 77.90
- Market capitalization: EUR 1.6 billion (as of October 26, 2026)
- 52-week range: EUR 30.20-EUR 82.55 (as of October 26, 2026)
- Sector / Industry: Consumer Staples / Drug Retailers
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report DAX.
